Bernard Combe Selected Research

Certolizumab Pegol

7/2021	Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.
1/2020	Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.
6/2017	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
12/2016	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
12/2014	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
3/2014	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
9/2012	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
6/2011	Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
5/2011	Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
1/2009	Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bernard Combe Research Topics

Disease

127	Rheumatoid Arthritis 01/2022 - 06/2002
28	Arthritis (Polyarthritis) 07/2022 - 07/2003
19	Rheumatic Diseases (Rheumatism) 01/2020 - 08/2009
17	Pain (Aches) 11/2022 - 06/2002
17	Psoriatic Arthritis 10/2022 - 10/2006
15	Inflammation (Inflammations) 11/2022 - 07/2006
14	Ankylosing Spondylitis 01/2022 - 10/2006
14	Necrosis 01/2021 - 06/2010
12	Infections 01/2021 - 06/2008
11	Fatigue 11/2022 - 01/2009
8	Neoplasms (Cancer) 09/2021 - 10/2011
6	Axial Spondyloarthritis 09/2021 - 05/2013
5	Synovitis 07/2015 - 06/2002
4	Osteoarthritis 07/2021 - 08/2010
3	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2021 - 01/2016
3	Lymphoma (Lymphomas) 01/2021 - 01/2011
3	Skin Neoplasms (Skin Cancer) 01/2020 - 04/2012
3	Back Pain (Backache) 01/2018 - 09/2012
3	Herpes Zoster 01/2018 - 07/2003
3	Spondylarthropathies 11/2012 - 10/2006
2	Chronic Disease (Chronic Diseases) 01/2022 - 01/2017
2	Human Influenza (Influenza) 12/2019 - 07/2014
2	Disease Progression 12/2016 - 12/2013
2	Experimental Arthritis 01/2016 - 08/2014
2	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 10/2014 - 04/2013
2	Sarcoidosis (Schaumann Disease) 10/2013 - 08/2009
2	Spondylarthritis (Spinal Arthritis) 02/2012 - 04/2011
2	Autoimmune Diseases (Autoimmune Disease) 01/2011 - 08/2005
2	Tuberculosis (Tuberculoses) 01/2011 - 06/2008
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 08/2010 - 07/2003
2	Hemorrhage 11/2003 - 11/2003
1	Diverticulitis 01/2022
1	Hypercholesterolemia 05/2021
1	COVID-19 01/2021

Drug/Important Bio-Agent (IBA)

43	Antirheumatic Agents (DMARD)IBA 10/2022 - 11/2004
33	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 07/2003
26	Tumor Necrosis Factor InhibitorsIBA 09/2021 - 11/2004
24	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2021 - 07/2003
23	Etanercept (Enbrel)FDA Link 01/2022 - 07/2003
23	Rituximab (Mabthera)FDA Link 01/2022 - 08/2010
21	Biological ProductsIBA 09/2021 - 08/2005
15	ametantrone (HAQ)IBA 11/2022 - 11/2003
15	tocilizumab (atlizumab)FDA Link 01/2022 - 01/2011
13	Infliximab (Remicade)FDA Link 01/2021 - 07/2003
13	AntibodiesIBA 11/2019 - 01/2006
11	Adalimumab (Humira)FDA Link 12/2021 - 06/2008
11	Certolizumab Pegol FDA Link 07/2021 - 11/2008
10	Abatacept (Orencia)FDA Link 01/2022 - 01/2011
10	C-Reactive ProteinIBA 03/2021 - 11/2003
10	Anti-Citrullinated Protein AntibodiesIBA 01/2021 - 09/2010
10	Pharmaceutical PreparationsIBA 01/2019 - 06/2003
8	ixekizumabIBA 10/2022 - 01/2020
8	Rheumatoid FactorIBA 01/2021 - 10/2013
7	GlucocorticoidsIBA 01/2021 - 07/2006
6	Monoclonal AntibodiesIBA 01/2022 - 06/2008
6	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2018 - 06/2003
6	Leflunomide (Arava)FDA LinkGeneric 10/2017 - 08/2005
6	golimumab FDA Link 06/2017 - 04/2012
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2008
5	LigandsIBA 01/2016 - 04/2005
4	Vitamin D FDA LinkGeneric 11/2020 - 05/2016
4	cyclic citrullinated peptideIBA 12/2016 - 01/2006
4	AutoantibodiesIBA 10/2014 - 01/2006
3	Biosimilar PharmaceuticalsIBA 01/2021 - 03/2014
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2011
3	baricitinibIBA 01/2019 - 01/2017
3	CytokinesIBA 01/2018 - 02/2011
3	Interleukin-6 (Interleukin 6)IBA 07/2015 - 04/2013
3	SteroidsIBA 04/2015 - 10/2007
3	Immunoglobulin M (IgM)IBA 12/2010 - 01/2009
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2022 - 08/2014
2	upadacitinibIBA 01/2022 - 01/2018
2	GLPG0634IBA 01/2022 - 01/2021
2	CholesterolIBA 05/2021 - 07/2006
2	CT-P13IBA 01/2021 - 01/2021
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2020 - 01/2018
2	VaccinesIBA 12/2019 - 01/2019
2	LipidsIBA 01/2018 - 06/2012
2	Interleukin-10 (Interleukin 10)IBA 01/2018 - 08/2014
2	LDL CholesterolIBA 03/2017 - 07/2006
2	OsteopontinIBA 01/2017 - 03/2015
2	OsteoprotegerinIBA 07/2015 - 04/2011
2	Anti-Idiotypic AntibodiesIBA 08/2014 - 01/2014
2	Peptides (Polypeptides)IBA 08/2014 - 01/2014
2	B-Cell Activating FactorIBA 08/2013 - 04/2013
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 04/2013 - 10/2012
2	Lymphotoxin-alpha (Lymphotoxin)IBA 07/2011 - 02/2011
2	Immunoglobulin G (IgG)IBA 01/2011 - 12/2009
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 07/2006 - 11/2003
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Protein SIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	N-(4-iodophenethyl)maleimide (IPEM)IBA 09/2021
1	secukinumabIBA 09/2021
1	4-hexyloxyaniline (HOA)IBA 07/2021
1	Messenger RNA (mRNA)IBA 01/2021

Therapy/Procedure

53	Therapeutics 01/2022 - 06/2003
7	Biological Therapy 01/2017 - 07/2007
2	Drug Therapy (Chemotherapy) 01/2022 - 07/2007
2	Aftercare (After-Treatment) 12/2016 - 09/2015